Related Experiment Video
Updated: Aug 7, 2026
08:15
Gastrointestinal Motility Monitor (GIMM)
Published on: December 1, 2010
Ethosuximide inducted changes in the gastro-intestinal tract
P Zagorchev1, V Sirakov, A Uchikov
1Department of Radiology, Medical Faculty, Higher Medical Institute, Plovdiv, Bulgaria.
Folia Medica
|April 17, 1999
Summary
Ethosuximide, used for childhood epilepsy, can cause gastrointestinal issues. Research indicates it reduces stomach and intestinal muscle activity by affecting calcium channels, leading to side effects.
Area of Science:
- Pharmacology
- Gastroenterology
- Neuroscience
Background:
- Ethosuximide is a common antiepileptic drug, particularly for petit mal seizures in children.
- Clinical observations suggest potential gastrointestinal (GI) side effects associated with ethosuximide treatment.
Observation:
- This research investigates ethosuximide-induced secondary effects on the GI tract.
- Roentgenological examination of patients revealed stomach and intestinal atony and reduced peristalsis.
Findings:
- In vitro studies on human stomach smooth muscle showed ethosuximide significantly reduces bioelectrical activity.
- The drug's effect is primarily on calcium (Ca+) dependent components, causing smooth muscle relaxation.
Implications:
- Reduced Ca+ influx into smooth muscle cells is proposed as a key mechanism for GI side effects.
- Understanding these mechanisms can inform strategies to mitigate ethosuximide-induced GI disturbances.
Related Concept Videos
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:20Drugs Affecting GI Tract Motility: Other Laxatives
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...